Free Trial

Becton, Dickinson and Company (BDX) FDA Events

Becton, Dickinson and Company logo
$177.13 +1.63 (+0.93%)
Closing price 03:59 PM Eastern
Extended Trading
$177.46 +0.33 (+0.18%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
FDA Events for Becton, Dickinson and Company (BDX)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Becton, Dickinson and Company (BDX). Over the past two years, Becton, Dickinson and Company has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as GalaFLEX. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

GalaFLEX LITE - FDA Regulatory Timeline and Events

GalaFLEX LITE is a drug developed by Becton, Dickinson and Company for the following indication: In Breast Implant Revision Surgery. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Becton, Dickinson and Company FDA Events - Frequently Asked Questions

As of now, Becton, Dickinson and Company (BDX) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Becton, Dickinson and Company (BDX) has reported FDA regulatory activity for GalaFLEX LITE.

The most recent FDA-related event for Becton, Dickinson and Company occurred on March 20, 2025, involving GalaFLEX LITE. The update was categorized as "Provided Update," with the company reporting: "BD (Becton, Dickinson and Company) announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery."

Currently, Becton, Dickinson and Company has one therapy (GalaFLEX LITE) targeting the following condition: In Breast Implant Revision Surgery.

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NYSE:BDX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners